MedTrace Logo

Immuno-based Profiling of knEe OA Patients to Predict reSponse to Regenerative Treatment

NCT06384040 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2024-04-30

No results posted yet for this study

Summary

Osteoarthritis (OA) is a highly prevalent degenerative musculoskeletal disease and a major cause of chronic disability worldwide. Its multifactorial origin contributes to determine the heterogeneous phenotypes and one unmet need is the lack of biomarkers to predict the individual response. Platelet-rich-plasma (PRP) injection is a minimally invasive autologous blood-derived approach for which we plan to define specific knee profiles predictive of response. We will take advantage of a unique multidisciplinary approach aimed at analysing clinics, imaging, and biomarkers of associated with clinical response. We will focus on inflammatory (Wnt system, IL1 pathway, PTX3) and antioxidant (primarily, DPP3/Keap1/Nrf2) pathways. We foresee that our results will allow a better allocation of immunomodulatory and regenerative therapies for a personalized approach in knee OA thus maximising the effectiveness of the healthcare allocation.

Conditions

  • Osteoarthritis, Knee

Interventions

PROCEDURE

platelet-rich plasma knee injection

platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder

Sponsors & Collaborators

  • Istituto Ortopedico Rizzoli

    collaborator OTHER

  • Istituto Clinico Humanitas

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-09-04
Completion
2024-10-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06384040 on ClinicalTrials.gov